3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
NIH
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
3
Plasma cell
1
Other hematologic neoplasm
1
Head & Neck
1
Genitourinary
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Tumor Lysis Syndrome
1
Tongue Neoplasms
1
Thyroid cancer, Hurthle cell
1
Thyroid Neoplasms
1
Thyroid Cancer, Papillary
1
Thromboembolism
1
Teratogenesis
1
Squamous Cell Carcinoma of Head and Neck
1
Sleepiness
1
Seizures
1
Salivary Gland Neoplasms
1
Renal Insufficiency
1
Rectal Neoplasms
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Peripheral Nervous System Diseases
1
Neoplasms, Second Primary
1
Lymphoma
1
Lymphoid Interstitial Pneumonia
1
Lung Diseases, Interstitial
1
Infections
1
Hypothyroidism
1
Hypotension, Orthostatic
1
Hypersensitivity
1
Hemorrhage
1
Heart Failure
1
Head and Neck Neoplasms
1
Fatigue
1
Dizziness
1
Digestive System Diseases
1
Coronary Artery Disease
1
Interventions
pembrolizumab
7
Cetuximab
5
selpercatinib
3
cemiplimab
3
Trastuzumab
3
Magnetic Resonance Spectroscopy
3
Gemcitabine
3
Erlotinib Hydrochloride
3
Bortezomib
3
sargramostim
2
motexafin gadolinium
2
entinostat
2
Specimen Handling
2
Radiotherapy
2
Oxaliplatin
2
Irinotecan
2
Fluorodeoxyglucose F18
2
Drug Therapy
2
Docetaxel
2
Biopsy
2
ulixertinib
1
tumor necrosis factor-alpha, CNGRC fusion protein, human
1
trastuzumab deruxtecan
1
trastuzumab biosimilar HLX02
1
trametinib
1
tislelizumab
1
tipifarnib
1
tanespimycin
1
spartalizumab
1
serabelisib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Colonic Neoplasms
×
Lenalidomide
×
Head & Neck
×
Clear all
NCT01254617
2020-03-13
ADCC
National Cancer Institute (NCI)
Phase 1
Completed
24 enrolled